How early can myocardial iron overload occur in beta thalassemia major?

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Yang, Gaohui ^a   Liu, Rongrong ^a   Peng, Peng ^a   Long, Liling ^a   Zhang, Xinhua ^b   Yang, Weijia ^c   Tan, Shaohong ^d   Pan, Hongfei ^e   Long, Xingjiang ^f   He, Taigang ^g,h   Anderson, Lisa ^g   Lai, Yongrong ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b The 303rd Hospital of PLA   (China)

^c Children Women Health Hospital of Guilin City   (China)

^d Department of Pediatrics Women and Children Hospital of Yulin   (China)

^e YOUJIANG MEDICAL UNIVERSITY FOR NATIONALITIES   (China)

^f LIUZHOU PEOPLE S HOSPITAL   (China)

^g ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^h ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; IRON;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CHILD; DISEASE SEVERITY; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEART HEMOSIDEROSIS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; PREVALENCE; THALASSEMIA MAJOR; BETA-THALASSEMIA; BLOOD; DIAGNOSIS; HEART DISEASES; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; IRON OVERLOAD; METABOLISM; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PROCEDURES; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; FEMALE; FERRITINS; HEART DISEASES; HUMANS; IRON; IRON OVERLOAD; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; MULTIVARIATE ANALYSIS; MYOCARDIUM; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 84899809507     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085379     Document Type: Article

References (41)

1. Modell B, Khan M, Darlison M. (2000) Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 355: 2051-2052. (Pubitemid 30339248)
2. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, et al.(2008) Improved survival of thalassaemia major in the UK and relation to T2*cardiovascular magnetic resonance. J Cardiovasc Magn Reson 10: 42.
3. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, et al. (2004) Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89: 1187-1193. (Pubitemid 39390442)
4. Kremastinos DT, Tsetsos GA, Tsiapras DP, Karavolias GK, Ladis VA, et al. (2001) Heart failure in beta thalassemia: a 5-year follow-up study. Am J Med 111: 349-354. (Pubitemid 32913666)
5. Brittenham GM, Badman DG. (2003) Noninvasive measurement of iron: report of an NIDDK workshop. Blood 101: 15-19. (Pubitemid 36025881)
6. Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, et al. (2009) Cardiac T2*magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 120: 1961-1968.
7. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, et al. (2002) Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 360: 516-520. (Pubitemid 35232104)
8. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, et al. (2007) A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115: 1876-1884. (Pubitemid 46598901)
9. Guidelines for clinical management of thalassaemia 2ND Revised Edition (2008) pp. 86.
10. Angastiniotis M, Modell B (1998) Global epidemiology of hemoglobin disorders. Ann N Y Acad Sci 850: 251-269. (Pubitemid 28369766)
11. Pan HF, Long GF, Li Q, Feng YN, Lei ZY, et al. (2007) Current status of thalassemia in minority populations in Guangxi, China. Clin Genet 71: 419-426. (Pubitemid 46730651)
12. Aessopos A, Farmakis D, Hatziliami A, Fragodimitri C, Karabatsos F, et al. (2004) Cardiac status in well-treated patients with thalassemia major. Eur J Haematol 73: 359-366. (Pubitemid 39349917)
13. Guidelines for clinical management of thalassaemia 2ND Revised Edition (2008) pp. 61-63.
14. Westwood M, Anderson LJ, Firmin DN, Gatehouse PD, Charrier CC, et al. (2003) A single breath-hold multiecho T2*cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 18: 33-39. (Pubitemid 36791266)
15. Maceira AM, Prasad SK, Khan M, Pennell DJ (2006) Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson 8: 417-426.
16. Alpendurada F, Carpenter JP, Deac M, Kirk P, Walker JM, et al. (2010) Relation of myocardial T2*to right ventricular function in thalassaemia major. Eur Heart J 31: 1648-1654.
17. He T, Zhang J, Carpenter JP, Feng Y, Smith GC, et al. (2013) Automated truncation method for myocardial T2*measurement in thalassemia. J Magn Reson Imaging 37: 479-483.
18. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. (2004) Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 103: 1934-1936. (Pubitemid 38268994)
19. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, et al. (1990) High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 84: 113-117. (Pubitemid 20361934)
20. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, et al. (2008) Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 10: 12.
21. Engle MA EM, Ch S. (1964) Late cardiac complictions of chronic, severe, refractory anemia with hemochromatosis. Circulation 30: 698-705.
22. Wood JC. (2008) Cardiac iron across different transfusion-dependent diseases. Blood Rev 22 Suppl 2: S14-21.
23. Tziomalos K, Perifanis V. (2010) Liver iron content determination by magnetic resonance imaging. World J Gastroenterol 16: 1587-1597.
24. Fitchett DH, Coltart DJ, Littler WA, Leyland MJ, Trueman T, et al. (1980) Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium. Cardiovasc Res 14: 719-724. (Pubitemid 11167199)
25. Barosi G, Arbustini E, Gavazzi A, Grasso M, Pucci A. (1989) Myocardial iron grading by endomyocardial biopsy. A clinico-pathologic study on iron overloaded patients. Eur J Haematol 42: 382-388. (Pubitemid 19131449)
26. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, et al. (1994) Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 331: 567-573. (Pubitemid 24265698)
27. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, et al. (1994) Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 331: 574-578. (Pubitemid 24265699)
28. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. (2004) Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 104: 263-269. (Pubitemid 38879867)
29. Wood JC, Origa R, Agus A, Matta G, Coates TD, Galanello R. (2008) Onset of cardiac iron loading in pediatric patients with thalassemia major. Haematologica 93: 917-920. (Pubitemid 351821730)
30. Fernandes JL, Fabron A Jr, Verissimo M. (2009) Early cardiac iron overload in children with transfusion-dependent anemias. Haematologica 94: 1776-1777.
31. Yong-rong Lai, Chun-fu Li, Shao-liang Huang, Qi-Li, Zhi-xiang Shen, et al. (2013) Efficacy of deferasirox for the treatment of iron overload in Chinese thalassemia major patients: results from a prospective, open-label, multicenter clinical trial. Transfus Med 2013 Dec;23(6):389-96. doi: 10.1111/tme.12077. Epub 2013 Oct 23.
32. Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, et al. (2006) Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson 8: 543-547.
33. Positano V, Pepe A, Santarelli MF, Ramazzotti A, Meloni A, et al. (2009) Multislice multiecho T2*cardiac magnetic resonance for the detection of heterogeneous myocardial iron distribution in thalassaemia patients. NMR Biomed 22: 707-715.
34. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, et al. (2001) Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22: 2171-2179. (Pubitemid 33139463)
35. Leung AW, Chu WC, Lam WW, Lee V, Li CK. (2009) Magnetic resonance imaging assessment of cardiac and liver iron load in transfusion dependent patients. Pediatr Blood Cancer 53: 1054-1059.
36. Christianson A HCP, Modell B (2006) March of Dimes Global Report on Birth Defects. New York, NY: March of Dimes Birth Defects Foundation.
37. Modell B, Darlison M. (2008) Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 86: 480-487. (Pubitemid 351821761)
38. Weatherall DJ, Clegg JB. (1996) Thalassemia-a global public health problem. Nat Med 2: 847-849. (Pubitemid 26296746)
39. Weatherall DJ, Clegg JB (2001) The thalassaemia syndromes. Oxford, Blackwell Science.
40. Bejaoui M, Guirat N. (2013) Beta thalassemia major in a developing country: epidemiological, clinical and evolutionary aspects. Mediterr J Hematol Infect Dis 5: e2013002.
41. Meng Q, Xu L, Zhang Y, Qian J, Cai M, et al. (2012) Trends in access to health services and financial protection in China between 2003 and 2011: a cross-sectional study. Lancet 379: 805-814.